Table 1 Baseline characteristics of RC patients with different treatment strategies.

From: Association of different treatment modalities for rectal cancer and second primary urinary system neoplasms, findings from SEER

 

SC

SCR

S

SR

p value

 

N = 2947

N = 14,318

N = 35,106

N = 3879

 

Age:

    

< 0.001

18 ~ 50

552 (18.7%)

2826 (19.7%)

3568 (10.2%)

418 (10.8%)

 

50 ~ 70

1674 (56.8%)

8383 (58.5%)

18,071 (51.5%)

2183 (56.3%)

 

≥70

721 (24.5%)

3109 (21.7%)

13,467 (38.4%)

1278 (32.9%)

 

Sex:

    

< 0.001

Female

1295 (43.9%)

5473 (38.2%)

16,192 (46.1%)

1520 (39.2%)

 

Male

1652 (56.1%)

8845 (61.8%)

18,914 (53.9%)

2359 (60.8%)

 

Race:

    

< 0.001

White

2361 (80.1%)

11,741 (82.0%)

29,268 (83.4%)

3404 (87.8%)

 

Black

175 (5.94%)

711 (4.97%)

1870 (5.33%)

179 (4.61%)

 

Other

411 (13.9%)

1866 (13.0%)

3968 (11.3%)

296 (7.63%)

 

Period:

    

< 0.001

1975 ~ 1984

256 (8.69%)

210 (1.47%)

9182 (26.2%)

1351 (34.8%)

 

1985 ~ 1994

492 (16.7%)

2069 (14.5%)

9146 (26.1%)

1718 (44.3%)

 

1995 ~ 2004

953 (32.3%)

5138 (35.9%)

8412 (24.0%)

562 (14.5%)

 

2005 ~ 2020

1246 (42.3%)

6901 (48.2%)

8366 (23.8%)

248 (6.39%)

 

Grade:

    

< 0.001

I

179 (6.07%)

920 (6.43%)

5714 (16.3%)

435 (11.2%)

 

II

2133 (72.4%)

9984 (69.7%)

18,245 (52.0%)

2385 (61.5%)

 

III

437 (14.8%)

2099 (14.7%)

2597 (7.40%)

565 (14.6%)

 

IV

38 (1.29%)

126 (0.88%)

135 (0.38%)

19 (0.49%)

 

Unknown

160 (5.43%)

1189 (8.30%)

8415 (24.0%)

475 (12.2%)

 

Histology:

    

< 0.001

Adenocarcinoma

2732 (92.7%)

13,116 (91.6%)

33,565 (95.6%)

3531 (91.0%)

 

Mucous tumor

184 (6.24%)

1011 (7.06%)

1140 (3.25%)

277 (7.14%)

 

Other

31 (1.05%)

191 (1.33%)

401 (1.14%)

71 (1.83%)

 

Origin:

    

< 0.001

Non-SHL

2758 (93.6%)

13,280 (92.8%)

33,445 (95.3%)

3690 (95.1%)

 

SHL

189 (6.41%)

1038 (7.25%)

1661 (4.73%)

189 (4.87%)

 

Total tumor number:

    

< 0.001

1

2376 (80.6%)

11,684 (81.6%)

27,062 (77.1%)

2929 (75.5%)

 

2

469 (15.9%)

2210 (15.4%)

6658 (19.0%)

784 (20.2%)

 

≥3

102 (3.46%)

424 (2.96%)

1386 (3.95%)

166 (4.28%)

 

Regional nodes

    

< 0.001

0

745 (25.3%)

6777 (47.3%)

11,833 (33.7%)

761 (19.6%)

 

1 ~ 3

1224 (41.5%)

3702 (25.9%)

1290 (3.67%)

332 (8.56%)

 

4 ~ 10

495 (16.8%)

1499 (10.5%)

392 (1.12%)

106 (2.73%)

 

>10

79 (2.68%)

255 (1.78%)

45 (0.13%)

18 (0.46%)

 

unknown

404 (13.7%)

2085 (14.6%)

21,546 (61.4%)

2662 (68.6%)

 
  1. Note: SC, Surgery plus Chemotherapy group; S, Surgery-only Group. SC, Surgery plus chemotherapy Group. SCR, Surgery combined with chemoradiotherapy Group. RC, Rectal Cancer. SPUNs, Second Primary Urinary System Neoplasms. Period, The year of RC diagnosis. Origin, Origin recode NHIA (Hispanic, Non-Hisp). Non-SHL, Non-Spanish-Hispanic-Latino. SHL, Spanish-Hispanic-Latino. Total tumor number, The total number of in situ/malignant tumors for the patient. Regional nodes, Regional nodes positive (1988+).
Back to article page